Skip to main content

LSE TECHNOLOGY APPROACH TO GENERATE INNOVATIVE KINASE INHIBITOR DRUGS

Obiettivo

Over the last decade, kinases have emerged as attractive therapeutic targets in inflammatory diseases. Numerous efforts in the pharmaceutical community are directed towards the discovery of small molecule inhibitors that regulate kinase function.
A number of issues need to be addressed when considering kinases as targets in inflammation. The combination of efficacy and favourable safety profile is often key for the successful treatment of chronic inflammatory and/or autoimmune diseases with kinase inhibitors.
The LSE (Low Systemic Exposure) approach is a Creabilis proprietary technology that generates innovative molecules with unique physico-chemical and pharmacological characteristics. LSE molecules are ‘topical by design’ molecules that share some common features. They combine high local concentration with poor systemic absorption and distribution. If absorbed, LSE molecules are rapidly eliminated from the systemic circulation (very short plasma half-life), thus generating no/low side effects. LSE approach has already been clinically validated through CT327, a selective topical kinase inhibitor that recently reported positive Phase 2a data in both psoriasis and atopic dermatitis.
This project will combine Creabilis experience and know-how on LSE modification of molecules with the sound systems biology and network pharmacology expertise of the University of Dundee to generate and bring to preclinical development a new generation of innovative molecules optimised for topical treatment of inflammatory diseases, such as psoriasis, atopic dermatitis and inflammatory bowel disease.
The generated lead compound(s) will be characterized by minimal or no systemic toxicity combined with efficacy and optimised selectivity. This would tremendously widen the range of patients affected by inflammatory pathologies that could benefit of topical kinase inhibition as a therapy and provide an innovative concept for new medicines to be developed.

Invito a presentare proposte

FP7-HEALTH-2012-INNOVATION-1
Vedi altri progetti per questo bando

Coordinatore

CREABILIS THERAPEUTICS SRL
Indirizzo
Via Ribes 5
10010 Colleretto Giacosa To
Italia

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Silvio Traversa (Dr.)
Contributo UE
€ 896 674,26

Partecipanti (5)

SERICHIM S.r.l.
Italia
Contributo UE
€ 178 254
Indirizzo
Piazzale Marinotti 1
33050 Torviscosa

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Pietro Delogu (Dr.)
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO

Partecipazione conclusa

Paesi Bassi
Contributo UE
€ 26 005,50
Indirizzo
Anna Van Buerenplein 1
2595 DA Den Haag

Mostra sulla mappa

Tipo di attività
Research Organisations
Contatto amministrativo
Robert Ostendorf (Dr.)
UNIVERSITY OF DUNDEE
United Kingdom
Contributo UE
€ 146 280
Indirizzo
Nethergate
DD1 4HN Dundee

Mostra sulla mappa

Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Ian Robertson (Mr.)
TNO TRISKELION BV

Partecipazione conclusa

Paesi Bassi
Indirizzo
Utrechtseweg 48
3704 HE Zeist

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
John Hoebe (Mr.)
KWS BIOTEST LIMITED
United Kingdom
Contributo UE
€ 202 467,24
Indirizzo
Medical Sciences Building University Walk
BS8 1TD Bristol

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Vicky Chen (Mrs.)